Evidence map›Paper›PMID 40270480›Full record

ArticleBiotechnology progress

Techno-economic analysis of membrane-based continuous capture chromatography platforms for large-scale antibody production.

Juan J Romero, Eleanor W Jenkins, Marc R Birtwistle, Scott M Husson

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Juan J RomeroDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina, USA.
Eleanor W JenkinsSchool of Mathematical and Statistical Sciences, Clemson University, Clemson, South Carolina, USA.
Marc R BirtwistleDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina, USA.
Scott M HussonDepartment of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina, USA.ORCID 0000-0002-8830-8530

Funding

Mechanistic Pharmacodynamic Modeling for Drug Combination ResponsesR35GM141891 · NIGMS · CLEMSON UNIVERSITY · PI BIRTWISTLE, MARC R. · 2021 to 2025
$2.1M
Strategies for continuous biologics purification with new affinity membranesR15GM131341 · NIGMS · CLEMSON UNIVERSITY · PI HUSSON, SCOTT M · 2018 to 2018
$422k
National Institute of General Medical Sciences of the National Institutes of Health R15GM131341National Institute of General Medical Sciences of the National Institutes of Health R35GM141891NIGMS NIH HHS R15 GM131341NIGMS NIH HHS R35 GM141891the National Science Foundation DMS-2011902
6 · The paper itself

Abstract

Continuous manufacturing platforms and membrane chromatography are process technologies with the potential to reduce production costs and minimize process variability in monoclonal antibody production. This study presents a simulation and optimization framework to perform techno-economic analyses of these strategies. Multi-objective optimization was used to compare batch and continuous multicolumn operating modes and membrane and resin process alternatives, revealing performance differences in productivity and cost of goods attributed to variations in dynamic binding capacity, media geometry, and process residence time. From the set of optimal process configurations, we selected one membrane and one resin platform alternative yielding the highest net present values to undergo sensitivity analyses involving variations in batch cadence and product selling price. For the scenarios considered in this work, membrane continuous platforms showed benefits in the cost of goods and process mass intensity. Their shorter residence time compared to resins positions them as a viable alternative for single-use capture chromatography. Moreover, this low residence time makes membrane platforms more flexible to changes in throughput, an essential feature for integrating capture into fully continuous processes.

Indexed as

Antibodies, MonoclonalChromatographyMembranes, ArtificialAnimalsAntibodies, MonoclonalMembranes, Artificialeconomic analysisLASSO‐regressionmonoclonal antibodiesmulti‐objective optimizationsurrogate function

Identifiers

PMID40270480
PMCPMC12353975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.